orforglipron eli lilly

Eli Lilly’s new pill keeps weight off

Lilly’s Oral Weight Loss Pill Succeeds In Phase 3 Trial

Eli Lilly and Co. announced Thursday, Dec. 18 that its experimental daily GLP-1 pill, orforglipron, successfully helped patients maintain significant weight loss after they stopped using popular injectable treatments like Wegovy and Zepbound.

GlobalData on MSN · 9h

Eli Lilly’s oral GLP-1RA maintains weight loss from injectable drugs

24/7 Wall St. on MSN · 4h

Did Eli Lilly Just Find the Holy Grail of Weight Loss?

Eli Lilly, Novo Nordisk file competing new weight-loss drugs with the FDA that could be game changers in obesity medicine

Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

BioPharma Dive

Lilly obesity pill, headed for quick FDA review, hits mark in ‘maintenance’ trial

Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...

PharmExec

Eli Lilly Announces Topline Results From Phase III Trial Studying Oral GLP-1 Therapy Orforglipron

Lilly’s Attain-Maintain Phase III results show that the oral GLP-1 orforglipron can effectively preserve weight loss after injectable therapy, positioning it as a potential long-term maintenance ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results